HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jeong, H.-J. Articles by Lee, M. C. Search for Related Content PubMed PubMed Citation Articles by Jeong, H.-J. Articles by Lee, M. C.

Usefulness of Whole-Body ¹⁸F-FDG PET in Patients with Suspected Metastatic Brain Tumors

¹ Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea
² Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
³ Department of Nuclear Medicine, Wonkwang University, College of Medicine, Iksan, Korea
⁴ Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea

The aim of this study was to evaluate the diagnostic value of whole-body ¹⁸F-FDG PET imaging in the differentiation of metastatic brain tumor from primary brain tumor and in the localization of the primary lesion in patients with metastatic brain tumor. Methods: The subjects consisted of 127 patients (77 men, 50 women; mean age ± SD, 55 ± 12 y) with brain masses that were suspected to be metastatic brain tumors on radiologic studies: 77 with confirmed metastatic brain tumor and 50 with primary brain tumor. Whole-body ¹⁸F-FDG PET was performed on all patients. When the abnormal lesion was detected outside the brain, we interpreted the brain lesion as metastatic brain tumor. Results: In 61 of the 77 patients with metastatic brain tumor, primary lesions were detected using whole-body ¹⁸F-FDG PET. Of the remaining 16 patients (all false-negative cases), 7 were classified as metastases of unknown origin. In 47 of the 50 patients with primary brain tumor, whole-body ¹⁸F-FDG PET did not show any other abnormal lesions. The sensitivity, specificity, positive and negative predictive values, and accuracy of PET for the detection of primary origin were 79.2%, 94.0%, 95.3%, 74.6%, and 85.0%, respectively. The most common primary origin of metastatic brain tumors on PET examination was lung cancer (48/61, 78.7%). The concordance rate between ¹⁸F-FDG PET and conventional radiologic work-up was 80% in identifying primary lesion. Unknown bone or bone marrow metastases and unsuspected distant metastases were found in 14 patients (18%) and 24 patients (31%), respectively, on PET examination. Conclusion: Screening the patients with suspected metastatic brain tumors using whole-body ¹⁸F-FDG PET could be helpful in differentiating metastatic brain tumor from primary brain tumor and in detecting the primary lesion.

Key Words: whole-body PET • FDG • metastatic brain tumor

This article has been cited by other articles:

				N. Kosaka, T. Tsuchida, H. Uematsu, H. Kimura, H. Okazawa, and H. Itoh 18F-FDG PET of Common Enhancing Malignant Brain Tumors Am. J. Roentgenol., June 1, 2008; 190(6): W365 - W369. [Abstract] [Full Text] [PDF]

				K. E. Posther, L. M. McCall, D. H. Harpole Jr., C. E. Reed, J. B. Putnam Jr., V. W. Rusch, and B. A. Siegel Yield of Brain 18F-FDG PET in Evaluating Patients with Potentially Operable Non-Small Cell Lung Cancer J. Nucl. Med., October 1, 2006; 47(10): 1607 - 1611. [Abstract] [Full Text] [PDF]

				H. Vesselle, E. Turcotte, L. Wiens, and D. Haynor Application of a Neural Network to Improve Nodal Staging Accuracy with 18F-FDG PET in Non-Small Cell Lung Cancer J. Nucl. Med., December 1, 2003; 44(12): 1918 - 1926. [Abstract] [Full Text] [PDF]